Research programme: RecA inhibitors - Synereca Pharmaceuticals
Latest Information Update: 26 Sep 2014
At a glance
- Originator Synereca Pharmaceuticals
- Class Small molecules
- Mechanism of Action Rec A recombinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Bacterial infections